Biogen complete $800m Nightstar Therapeutics acquisition

Biogen has completed its $800 million acquisition of Nightstar Therapeutics (NST).

The deal – originally announced in March – has added two mid- to late-stage clinical assets to Biogen’s pipeline alongside preclinical programmes in ophthalmology.

“Today marks a significant achievement for Biogen,” said CEO Michel Vounatsos.

“The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities.

“We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news